The STAR Data Reporting Guidelines for Clinical High Altitude Research.
Monika Brodmann Maeder, Hermann Brugger, Matiram Pun...
https://pubmed.ncbi.nlm.nih.gov/29596018/Actively Recruiting
Led by Third Military Medical University · Updated on 2026-08-11
208
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether High-flow Nasal Cannula Oxygen Therapy HFNC offers better respiratory support than Conventional Oxygen Therapy COT in patients suffering from High-Altitude Pulmonary Edema HAPE. HAPE is a serious condition occurring at high altitudes, and while COT is the standard treatment, the effectiveness of HFNC in this specific context is not well understood. This study aims to clarify the role of HFNC in improving respiratory function and speeding recovery for HAPE patients. Participants are randomly assigned to one of two groups one receiving HFNC with a specialized system that includes active humidification and heated-wire circuits delivered through a wide nasal cannula, alongside standard medical care the other receiving COT plus standard medical care. The study compares these two oxygen therapies during the treatment period lasting around 3 to 5 days, with monitoring up to 7 days to assess treatment success and other health outcomes. During the study, participants undergo assessments such as lung CT scans, oxygen saturation monitoring, and evaluations of oxygen therapy-related complications. Researchers track the time to stop supplemental oxygen, changes in lung severity scores, and the proportion of treatment failures. Participants are observed from the start of treatment until discharge, with safety and treatment effectiveness measured closely throughout the approximately one-week study period.
CONDITIONS
High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema
Y
Yiding Li, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Third Military Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 3 to 5 days
Participants receive either High-flow Nasal Cannula Oxygen Therapy or Conventional Oxygen Therapy alongside standard medical care to support breathing and recovery from High-Altitude Pulmonary Edema.
Daily assessments during treatment
Duration - Up to 7 days
Participants are monitored up to about 7 days after starting treatment to assess treatment success, lung condition changes, oxygen levels, and any complications.
Regular health checks until discharge
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Monika Brodmann Maeder, Hermann Brugger, Matiram Pun...
https://pubmed.ncbi.nlm.nih.gov/29596018/Jean-Pierre Frat, Arnaud W Thille, Alain Mercat...
https://pubmed.ncbi.nlm.nih.gov/25981908/B Rochwerg, D Granton, D X Wang...
https://pubmed.ncbi.nlm.nih.gov/30888444/RENOVATE Investigators and the BRICNet Authors, Israel S Maia, Letícia Kawano-Dourado...
https://pubmed.ncbi.nlm.nih.gov/39657981/Gustavo A Ospina-Tascón, Luis Eduardo Calderón-Tapia, Alberto F García...
https://pubmed.ncbi.nlm.nih.gov/34874419/Melissa A Warren, Zhiguou Zhao, Tatsuki Koyama...
https://pubmed.ncbi.nlm.nih.gov/29903755/Andrew M Luks, Beth A Beidleman, Luanne Freer...
https://pubmed.ncbi.nlm.nih.gov/37833187/Third Military Medical University
Lead Sponsor